| Translational Therapies |
| Knowledge of the basic biology
underlying the development and progression of
breast cancer is
growing at a dramatic pace. This information
is being rapidly translated from the lab to the
clinic
in the form of new diagnostic and prognostic
tools and is providing new targets for drug development.
Genomic tools are increasingly being utilized
to categorize breast cancer into biologic subtypes,
assess recurrence risk, and identify patients
most
likely to derive benefit from conventional chemotherapies
and new targeted agents. In addition, technologies
for detecting micrometastases, circulating tumor
cells, and circulating endothelial calls are
under investigation as tools for prognosticating
outcomes
and evaluating response to therapy. This expanding
armamentarium of technologies will aid in the
individualization and optimization of therapies
in an environment
of ever-growing treatment options. |
| |
LECTURES
|
Breast Cancer Highlights: Updates from the 2007 San Antonio Breast Cancer Symposium
January 31, 2008
Kansas City, MO |
|
Breast Cancer Highlights: Updates from the 2007 San Antonio Breast Cancer Symposium
January 24, 2008
Atlanta, GA |
|
| Translating the Complexities of Cancer Development Into Novel Therapeutics
|
|
Controversies in Biologic Therapy of Breast Cancer
September 7, 2007
San Francisco, CA |
|
2 AMA PRA Category
1 Credits™
Expiration date: September 24, 2008 |
Beyond Taxanes: New Chemotherapeutic Options for Patients With Refractory Metastatic Breast Cancer
September 7, 2007
San Francisco, CA |
|
2 AMA PRA Category
1 Credits™
Expiration date: September 24, 2008 |
Current Trends in Breast Cancer
January 13, 20-February 3, 24, 2007
2007 Series
- New Developments in Adjuvant Chemotherapy
- Controversies in Adjuvant Hormonal Therapy
- Adjuvant HER2-Directed Therapy: Candidates and Practical Management
- Novel Preoperative Therapy Strategies
- Treatment Insights Based on Molecular Subtypes and Novel Diagnostics
- New Insights Into Optimizing Local Control
- Evolving Chemotherapies and Hormonal Therapies for Metastatic Breast Cancer
- Novel Biologic Agents With Clinical Promise
- Management of Therapy-Related Toxicities
- Focus on the Host: Evolving Concepts
|
|
|
Biological Strategies to Treat Breast Cancer
- Biologic Agents in Advanced Breast Cancer: Current Data and Future Directions
- Biologic Agents in Adjuvant Breast Cancer: State-of-the-Art Therapy and Current Challenges
- Using Antibodies to Deliver Toxic Payloads: Rationale and Potential Utility in Breast Cancer
- Novel Antibodies Inhibiting Signal Transduction as an Approach to Treat Breast Cancer
- New Horizons With Antiangiogenic Therapies in Breast Cancer
|
|
|
|
Controversies in Breast Cancer Adjuvant and Neoadjuvant Therapy 2006
September 8-10, 2006 |
- Key Diagnostic Assessments in Breast Cancer
- Evolving Local Control Issues in Breast Cancer
- Treatment of Hormone Receptor–Positive Breast Cancer
- Adjuvant Treatment of HER2-Driven Breast Cancer
- Treating ER, PR, HER2-Negative Breast Cancer
- Lifestyle, Genetics, and Breast Cancer Outcome
|
|
5th Annual International Congress on the Future of Breast Cancer
August 3-6, 2006
- Best of Breast Cancer Research
- Optimizing Endocrine Therapy
- Molecular Mechanisms of Endocrine Resistance
- Supportive Care Breakfast Symposium
- Predictive and Prognostic Factors for Adjuvant Therapy
- Emerging Chemotherapy Strategies
- Targeting the HER Axis in Breast Cancer
- Targeting Angiogenesis in Breast Cancer
- New Agents Breakfast Symposium
- Impact of Local Control on Overall Outcomes
- Maintaining Bone Health
- Optimizing Chemotherapy
- Practical Issues in Breast Cancer Treatment
- Breast Cancer Genetics and Biology
|
|
|
| Novel
Approaches to Overcoming the Neoplastic Phenotype |
| |
|
|
| |
| |
PUBLICATIONS
|
 |
April 2008
1 AMA
PRA Category 1 Credit™
Expiration date: June 4, 2009
-
Multigene Assays: A Window Into Breast Cancer Behavior
|
|
 |
February
2008
1 AMA
PRA Category 1 Credits™
Expiration date: March 10, 2009
- Single vs. Combination Therapy: Which Agents and What Clinical Situation?
- Chemotherapy and Biologically Targeted Agents: Synergy and Side-Effect Profile
- LABC as aModel for the Study and Optimization of Chemotherapeutic Regimens
- Protein and Genetic Markers in Deciding Optimal Chemotherapy
|
|
 |
Vol.1 No. 1
1 AMA PRA
Category 1 Credit™
Expiration date: March 3, 2009
- HER2-Positive Early-Stage Breast Cancer: Decision-Making and Practical Management
- Role of Genomics and Emerging Novel Molecular Diagnostic Tests in the Routine Management of Early-Stage Breast Cancer
|
|
 |
December 2007
1 AMA PRA
Category 1 Credit™
Expiration date: December 22, 2008
- Who Needs Adjuvant HER2-Targeted
Therapy?
- Novel Therapies for HER2-Positive Breast
Cancer
- Confusion on the HER2 Front: Not All
Decisions
Are Black and White
- Inhibiting the Tumor Microenvironment
- Targeting Oncogene Addiction in Breast
Cancer:
Key Pathways and Novel Targets
|
|
 |
Vol. 8, No. 4
1 AMA PRA
Category 1 Credit™
Expiration date: December 14, 2008
- Rationale and Clinical Data for Combined Inhibition of HER2 and Vascular Endothelial Growth Factor Receptor Pathways in Breast Cancer
- Genomic Rearrangements in Breast
Cancer: Clinical Implications
- Putative Breast Cancer Stem Cells as Therapeutic Targets
|
|
 |
Vol. 6, No. 1
1 AMA PRA
Category 1 Credit™
Expiration date: December 7, 2008
- Novel Strategies for Treating Ovarian Cancer
- Emerging Monoclonal Antibodies for the Treatment
of HER2-Positive Breast Cancer
|
|
 |
November 2007
1 AMA PRA
Category 1 Credit™
Expiration date: November 30, 2008
|
 |
November 2007
1 AMA PRA
Category 1 Credit™
Expiration date: November 20, 2008
- Optimizing Adjuvant Therapy With HER2-Targeted MoAbs
- Clinical Utility and Future Prospects of Small-Molecule HER TKIs
- Breast Cancer Resistant to HER2-Targeted Therapies
- Clinical Utility and the Future of Angiogenesis Inhibitor Therapy
- Emerging Applications of IGF-1R–Targeted Therapy
|
|
 |
November 2007
1 AMA PRA
Category 1 Credit™
Expiration date: November 20, 2008
- HER2-Targeted Therapy in Early-Stage Breast Cancer
- Emerging Targeting Agents in HER2+ Breast Cancer
- Angiogenesis Inhibition in Advanced Breast Cancer
- Multiplying the Benefits: Novel Combinations of Targeted Agents
- c-Myc Amplification and Other Genetic Alterations in HER2+ Breast Cancer
|
|
 |
Vol. 4, No. 9
1 AMA PRA
Category 1 Credit™
Expiration date: November 20, 2008
- Treatment of a Premenopausal Patient With HR-Positive/Node-Negative Breast Cancer With Adjuvant Therapy
|
|
 |
November 2007
1 AMA
PRA Category 1 Credit™
Expiration date: November 20, 2008
- Combining VEGF and EGFR Inhibition in NSCLC
- Second-Generation Inhibitors of the VEGFR Tyrosine Kinase
- Small-Molecule TKIs in the Treatment of Advanced Thyroid Cancer
- Harnessing SPARC Protein for Uptake of Chemotherapy in Tumors
- Current Data on Raf/MEK Inhibitors in Melanoma and Other Cancers
- Understanding the Kinome and Its Role in Cancer Pathogenesis
|
|
 |
Vol. 4, No. 7
1 AMA PRA
Category 1 Credit™
Expiration date: October 31, 2008
- Adjuvant Chemotherapy Plus HER2-Targeted Therapy in HER2-Positive LABC
|
|
 |
August
2007
1 AMA
PRA Category 1 Credit™
Expiration date: August 31, 2008
- Increasing the Therapeutic Index of Traditional Chemotherapeutics
- Role of the Tumor Stroma in Breast Cancer and Treatment
- Immune-Mediated Antitumor Effects With Antibody Therapy
|
|
| |
